![]() ![]() The seroprevalence of CMV varies geographically and is higher in developing countries, with rates reaching up to 100%, likely resulting from poor socio-economic status and over-crowding which facilitate viral transmission through close contacts. ![]() Infection is usually acquired early in life through contact with infected body fluids such as saliva. This article provides a brief overview of the contemporary epidemiology, clinical presentation, diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients.ĬMV is a ubiquitous virus, with a worldwide distribution. ![]() Viral load quantification is now undergoing standardization, and this will permit the generation of clinically relevant viral thresholds for the management of patients. Novel antiviral drugs with unique mechanisms of action and lesser toxicity are being developed. There is now increasing interest in the development of an effective vaccine for prevention. Emerging data suggests that immunologic monitoring may be useful in predicting the risk of late onset CMV disease. Late-onset CMV disease continues to be a major problem in high-risk patients after completion of antiviral prophylaxis. Patients may develop asymptomatic viremia, CMV syndrome or tissue-invasive disease. It can affect allograft function and increase patient morbidity and mortality through a number of direct and indirect effects. Cytomegalovirus (CMV) continues to have a tremendous impact in solid organ transplantation despite remarkable advances in its diagnosis, prevention and treatment. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |